"Karen's breadth of expertise in research and development, paired with her exceptional leadership skills, brings great value to Acceleron as we work to execute on our vision to build therapeutic area leadership across hematological, neuromuscular, and pulmonary diseases," said Francois Nader, M.D., Chairman of Acceleron's board of directors. "We are pleased to welcome her to the Acceleron board."
Dr. Smith currently serves as Executive Vice President, Global Head R&D,
and Chief Medical Officer of
"Acceleron's internal research and development efforts have generated multiple clinical-stage programs with the potential to transform the lives of patients suffering from serious and rare diseases," said Dr. Smith. "I look forward to working with the Acceleron team as they strive to build category leadership in multiple disease areas, and advance their programs through the clinic."
"On behalf of Acceleron's board, shareholders and employees, I would
like to applaud and recognize Terry's many contributions over the last
12 years as a truly dedicated board member. His expertise and broad
industry knowledge helped guide the Company from founding through the
successful IPO in 2013 and beyond. We greatly appreciate his work, time,
and dedication to Acceleron," said
Acceleron is a Cambridge-based, clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research and development efforts in hematologic, neuromuscular, and pulmonary diseases. In hematology, the Company and its global collaboration partner, Celgene, are developing luspatercept for the treatment of chronic anemia in myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing its neuromuscular franchise with two distinct Myostatin+ agents, ACE-083 and ACE-2494, and a pulmonary program with a Phase 2 trial of sotatercept planned in pulmonary arterial hypertension.
Vice President, Investor Relations and Corporate Communications
Manager, Investor Relations and Corporate Communications
News Provided by Acquire Media